Inside the ICU: new study tracks tough pneumonia cases
NCT ID NCT07479355
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 100 adults hospitalized in intensive care units with severe pneumonia caused by Mycoplasma or Chlamydia bacteria. Researchers will track how patients are treated, how long they stay in the hospital, and how many survive. They will also check for antibiotic resistance. The goal is to better understand these serious infections and improve future care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better identify and treat severe pneumonia caused by these bacteria, potentially reducing ICU deaths.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any new drug or therapy, so it cannot directly improve patient outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHLAMYDIA PNEUMONIAE PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medecine intensive-reanimation
Le Kremlin-Bicêtre, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI could outsmart bacteria: a smarter way to choose antibiotics?
- Breathing technique may outperform spirometry for smog pneumonia recovery
- A gentle touch against coughs and colds: could manual therapy shorten respiratory illness?
- Can a smart oxygen device shorten hospital stays for pneumonia?
- Could everyday supplements shield your lungs?
- Can a simple inhaled combo keep pneumonia patients off ventilators?